UY36327A - Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y sus usos en el tratamiento de una afección mediada por el receptor de glucocorticoides - Google Patents

Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y sus usos en el tratamiento de una afección mediada por el receptor de glucocorticoides

Info

Publication number
UY36327A
UY36327A UY0001036327A UY36327A UY36327A UY 36327 A UY36327 A UY 36327A UY 0001036327 A UY0001036327 A UY 0001036327A UY 36327 A UY36327 A UY 36327A UY 36327 A UY36327 A UY 36327A
Authority
UY
Uruguay
Prior art keywords
compounds
oxo
treatment
dihidropiridin
alquil
Prior art date
Application number
UY0001036327A
Other languages
English (en)
Inventor
Lena Elisabeth Ripa
Hemmerling Martin
Edman Karl
Matti Juhani Lepistö
Lawitz Karolina
Llinas Antonio
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54252264&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY36327(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY36327A publication Critical patent/UY36327A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere en forma general a los compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo (incluyendo sales de los mismos). La presente invención asimismo se refiere a las composiciones farmacéuticas y a los kits que comprenden dichos compuestos, a los usos de dichos compuestos (incluyendo métodos de tratamiento y preparación de medicamentos), y a los procesos para preparar dichos compuestos.
UY0001036327A 2014-09-26 2015-09-25 Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y sus usos en el tratamiento de una afección mediada por el receptor de glucocorticoides UY36327A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462055822P 2014-09-26 2014-09-26

Publications (1)

Publication Number Publication Date
UY36327A true UY36327A (es) 2016-04-01

Family

ID=54252264

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036327A UY36327A (es) 2014-09-26 2015-09-25 Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y sus usos en el tratamiento de una afección mediada por el receptor de glucocorticoides

Country Status (30)

Country Link
US (1) US10196374B2 (es)
EP (1) EP3197878B1 (es)
JP (1) JP6430000B2 (es)
KR (1) KR101866706B1 (es)
CN (1) CN107001320B (es)
AP (1) AP2017009819A0 (es)
AR (1) AR105549A1 (es)
AU (1) AU2015323817B2 (es)
BR (1) BR112017006085B1 (es)
CA (1) CA2962312C (es)
CL (1) CL2017000715A1 (es)
CO (1) CO2017003955A2 (es)
CR (1) CR20170106A (es)
DO (1) DOP2017000064A (es)
EA (1) EA031945B1 (es)
ES (1) ES2751640T3 (es)
GT (1) GT201700058A (es)
IL (1) IL250886A0 (es)
MX (1) MX2017003697A (es)
NI (1) NI201700038A (es)
NZ (1) NZ730250A (es)
PE (1) PE20171110A1 (es)
PH (1) PH12017500533A1 (es)
SG (1) SG11201702225VA (es)
SV (1) SV2017005412A (es)
TN (1) TN2017000096A1 (es)
TW (1) TW201619146A (es)
UY (1) UY36327A (es)
WO (1) WO2016046260A1 (es)
ZA (1) ZA201702720B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017161518A1 (en) * 2016-03-23 2017-09-28 Astrazeneca Ab New physical form
EP3728219B1 (en) 2017-12-18 2022-04-13 Grünenthal GmbH Substituted pyrrolidine amides i
TW201927769A (zh) 2017-12-18 2019-07-16 德商歌林達有限公司 經取代之吡咯啶醯胺ｉｉ
WO2020144375A1 (en) 2019-01-11 2020-07-16 Grünenthal GmbH Substituted pyrrolidine amides iii
EP3986885B1 (en) 2019-06-19 2023-05-03 Grünenthal GmbH Substituted pyrrolidine amides iv
EP3986886A2 (en) 2019-06-19 2022-04-27 Grünenthal GmbH Substituted pyrrolidine amides v
US20230167068A1 (en) * 2019-12-31 2023-06-01 Medshine Discovery Inc. Benzopyrazole compound
WO2022008705A1 (en) 2020-07-09 2022-01-13 Grünenthal GmbH Substituted pyrrolidine amines and amides as mediator of the glucocortoid receptor
WO2022012456A1 (en) * 2020-07-17 2022-01-20 Chengdu Easton Biopharmaceuticals Co., Ltd. Novel heterocyclic compounds as bet inhibitors
WO2023041695A1 (en) 2021-09-20 2023-03-23 Astrazeneca Ab Methods of treating inflammatory diseases with a selective glucocorticoid receptor modulator

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200700140A1 (ru) * 2004-07-16 2007-08-31 Янссен Фармацевтика Н.В. Димерные соединения пиперидина, пиперазина или морфолина или их семичленные аналоги, предназначенные для лечения нейродегенеративных нарушений
JO2754B1 (en) * 2006-12-21 2014-03-15 استرازينكا ايه بي Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders
TW200951114A (en) * 2008-05-20 2009-12-16 Astrazeneca Ab Phenyl or pyridinyl substituted indazoles derivatives

Also Published As

Publication number Publication date
CN107001320A (zh) 2017-08-01
DOP2017000064A (es) 2017-03-31
AR105549A1 (es) 2017-10-18
IL250886A0 (en) 2017-04-30
EA201790496A1 (ru) 2018-03-30
SG11201702225VA (en) 2017-04-27
MX2017003697A (es) 2017-06-26
KR20170042785A (ko) 2017-04-19
CA2962312C (en) 2019-01-15
PE20171110A1 (es) 2017-08-07
JP6430000B2 (ja) 2018-11-28
ES2751640T3 (es) 2020-04-01
CR20170106A (es) 2017-09-01
US10196374B2 (en) 2019-02-05
AU2015323817B2 (en) 2018-11-01
BR112017006085A2 (pt) 2017-12-19
EP3197878A1 (en) 2017-08-02
PH12017500533A1 (en) 2017-08-07
CA2962312A1 (en) 2016-03-31
EP3197878B1 (en) 2019-07-24
WO2016046260A8 (en) 2017-04-13
JP2017529369A (ja) 2017-10-05
NZ730250A (en) 2018-03-23
ZA201702720B (en) 2019-06-26
WO2016046260A1 (en) 2016-03-31
CL2017000715A1 (es) 2017-11-10
NI201700038A (es) 2018-01-05
TW201619146A (zh) 2016-06-01
AU2015323817A1 (en) 2017-04-06
TN2017000096A1 (en) 2018-07-04
GT201700058A (es) 2019-08-12
US20170298041A1 (en) 2017-10-19
EA031945B1 (ru) 2019-03-29
BR112017006085B1 (pt) 2023-03-07
CN107001320B (zh) 2019-09-20
KR101866706B1 (ko) 2018-06-11
CO2017003955A2 (es) 2017-05-10
SV2017005412A (es) 2017-10-23
AP2017009819A0 (en) 2017-03-31

Similar Documents

Publication Publication Date Title
UY36327A (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y sus usos en el tratamiento de una afección mediada por el receptor de glucocorticoides
ECSP17081744A (es) Nuevos derivados hidroxiéster,un proceso para su preparación y composiciones farmacéuticas que los contienen
UY35980A (es) Derivados de sulfamoilpirrolamida como inhibidores del hbv y composiciones farmacéuticas que los contienen
DOP2017000151A (es) Derivados de quinazolina utilizados para tratar el vih
CO2018000648A2 (es) Compuestos de piridina sustituidos, intermediarios para su preparación y composiciones que los comprenden
BR112018006243A2 (pt) formas de cristal de mononucleotídeo de beta-nicotinamida
CO2017001884A2 (es) Polimorfos de selinexor
UY35210A (es) Inhibidores de autotaxina
GT201600147A (es) Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2
UY36126A (es) ?compuestos de 6,8-dioxabiciclo[3.2.1]octano-2,3-diol sustituidos como agentes de direccionamiento al asgpr?.
DOP2018000062A (es) Piridinona dicaboxamidas para uso como inhibidores de bromodominio
CO2017002472A2 (es) Formulación de acetato de abiraterona
ECSP16074478A (es) Compuestos novedosos
UY36195A (es) Amidas de benzoxazinona como reguladores del receptor mineralocorticoide
CO2017000950A2 (es) Compuestos que comprenden oligonucleótidos modificados dirigidos a mir-103 y/o mir-107 para trastornos metabólicos
BR112016028316A2 (pt) composição farmacêutica oral de isotretinoina, seu processo de preparação e método de tratamento
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
GT201600252A (es) Derivados de naftiridinadiona
CR20170090A (es) Derivados de terahidroquinolina como inhibidores del bromodominio
CL2017000707A1 (es) Derivados de nucleosidos sustituidos de 4'-vinilo como inhibidores de la replicación del arn del virus sincicial respiratorio
DOP2016000161A (es) Ureas asimétricas p- sustituidas y usos médicos de las mismas.
BR112016028083A2 (pt) Composição oral farmacêutica de isotretinoina e seu processo de preparação
DOP2016000325A (es) Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas
UY36393A (es) Síntesis de inhibidor de pi3k y sales del mismo
UY36464A (es) Compuestos de quinazolina

Legal Events

Date Code Title Description
104 Application deemed to be withdrawn (no substantive examination fee paid)

Effective date: 20201204